GDP-L-fucose synthase (FX protein) is a novel dual modulator of calcium oxalate kidney stone-forming processes
5
item.page.dc.date.issued
2026-02-01
item.page.dc.type
item.page.dc.identifier.issn
01418130
item.page.dc.identifier.eissn
18790003
item.page.dc.identifier.doi
item.page.dc.identifier.scopus
2-s2.0-105028969529
item.page.oaire.citation.title
International Journal of Biological Macromolecules
item.page.oaire.citation.volume
346
item.page.dc.rights.holder
SCOPUS
item.page.dc.identifier.citation
International Journal of Biological Macromolecules Vol.346 (2026)
punsarn.item.page.citation
Yoodee S., Suebsuk Y., Hadpech S., Detsangiamsak S., Malaitad T., Sukphan S., Plumworasawat S., Thongboonkerd V. GDP-L-fucose synthase (FX protein) is a novel dual modulator of calcium oxalate kidney stone-forming processes. International Journal of Biological Macromolecules Vol.346 (2026). doi:10.1016/j.ijbiomac.2026.150560 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/114858
item.page.dc.title
GDP-L-fucose synthase (FX protein) is a novel dual modulator of calcium oxalate kidney stone-forming processes
item.page.dc.contributor.author
item.page.oairecerif.author.affiliation
item.page.dc.contributor.correspondence
item.page.dc.contributor.other
item.page.dc.description.abstract
GDP-L-fucose synthase (or FX protein) has recently been identified in the urine from subjects with calcium oxalate (CaOx) kidney stones, but not in the normal urine. However, its role in kidney stone formation was unknown. We, therefore, produced and purified recombinant human FX protein and examined its stone-modulating effects using various assays compared with blank and negative controls. Crystal assays revealed that the FX protein promoted CaOx crystallization, crystal aggregation and crystal invasion through extracellular matrix (ECM). On the other hand, FX inhibited CaOx crystal growth and crystal-cell adhesion. Potential mechanisms underlying its crystal modulation were investigated. Ca<sup>2+</sup>- and Ox<sup>2−</sup>-binding affinity assays demonstrated that FX effectively bound both Ca<sup>2+</sup> and Ox<sup>2−</sup> ions. Immunofluorescence staining using a monoclonal antibody specific to the human FX protein revealed the direct binding of this protein to CaOx crystal surfaces. In conclusion, our findings indicate that the human FX protein is a novel dual CaOx stone modulator. While it promotes crystallization, aggregation and ECM invasion of CaOx crystals, it inhibits the crystal growth and adhesion to renal cells via the binding with free Ca<sup>2+</sup> and Ox<sup>2−</sup> ions as well as the crystal surfaces.
